SCHEMBL4813992

SCHEMBL4813992

[O]CN[C@H]1CC[C@@H](O)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.48
DPP4 P27487 1/20 0.37
LMNA P02545 1/20 0.36
GBA1 P04062 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CNR1 P21554 1/20 0.36
TBXA2R P21731 1/20 0.36
HRH2 P25021 1/20 0.36
SLC6A4 P31645 1/20 0.36
KCNH2 Q12809 1/20 0.36
HIF1A Q16665 1/20 0.36
TSHR P16473 2/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
SHBG P04278 1/20 0.31
LTA4H P09960 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4814571 1.00 EPHX2 (0.48) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL4813989 1.00 EPHX2 (0.48) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL3429060 0.80 EPHX2 (0.44) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL3431189 0.80 EPHX2 (0.44) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL14685712 0.79 EPHX2 (0.42) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL23172207 0.74 EPHX2 (0.42) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL1487970 0.74 KCNH2 (0.43) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL12468805 0.74 KCNH2 (0.43) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL3471037 0.74 KCNH2 (0.43) EPHX2DPP4LMNAGBA1CYP1A2
SCHEMBL4813112 0.74 EPHX1 (0.40) TSHRTDP1LTA4HKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
EP-1603885-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2005-12-14 EP disclosed
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBVIE INC. 2004-12-23 US disclosed
WO-2004080973-A1 FUSED TRI AND TETRA-CYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259904-A1 Fused tri and tetra-cyclic pyrazole kinase inhibitors TK1, MAP3K19, MAP3K20 EPHX2 3106/4885DPP4 3139/4885LMNA 3785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.